{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T01:58:33Z","timestamp":1787104713917,"version":"build-2736575974"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["22ZR1474400"],"award-info":[{"award-number":["22ZR1474400"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFA1800804"],"award-info":[{"award-number":["2023YFA1800804"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22277128"],"award-info":[{"award-number":["22277128"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22307132"],"award-info":[{"award-number":["22307132"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015796","name":"Shanghai Lingjun Program","doi-asserted-by":"publisher","award":["22YF1457500"],"award-info":[{"award-number":["22YF1457500"]}],"id":[{"id":"10.13039\/100015796","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.bmc.2025.118265","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T19:26:14Z","timestamp":1748978774000},"page":"118265","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Design, synthesis and structure-activity relationship studies of novel macrocyclic 2,4-diaminopyrimidines as HPK1 inhibitors"],"prefix":"10.1016","volume":"128","author":[{"given":"Feifei","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiarui","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunlai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoliang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linghua","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0845-0260","authenticated-orcid":false,"given":"Shilin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bmc.2025.118265_b0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.bmc.2025.118265_b0010","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nrc.2016.2","article-title":"Acquired resistance to immunotherapy and future challenges","volume":"16","author":"Restifo","year":"2016","journal-title":"Nat Rev Cancer"},{"issue":"21","key":"10.1016\/j.bmc.2025.118265_b0015","doi-asserted-by":"crossref","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","article-title":"Hallmarks of response, resistance, and toxicity to immune checkpoint blockade","volume":"184","author":"Morad","year":"2021","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.bmc.2025.118265_b0020","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-Related Adverse Events Associated with Immune Checkpoint Blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.bmc.2025.118265_b0025","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.bmc.2025.118265_b0030","doi-asserted-by":"crossref","unstructured":"M.C. Hu, X. Qiu Wr Fau - Wang, C.F. Wang X Fau - Meyer, T.H. Meyer Cf Fau - Tan, T.H. Tan, Human HPK1, a novel human hematopoietic progenitor kinase that activates the JNK\/SAPK kinase cascade. Genes Dev. 1996; 10 (18): 2251\u20132264. doi: 10.1101\/gad.10.18.2251.","DOI":"10.1101\/gad.10.18.2251"},{"issue":"3","key":"10.1016\/j.bmc.2025.118265_b0035","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1084\/jem.20062066","article-title":"A novel pathway down-modulating T cell activation involves HPK-1-dependent recruitment of 14-3-3 proteins on SLP-76","volume":"204","author":"Di Bartolo","year":"2007","journal-title":"J Exp Med"},{"issue":"5","key":"10.1016\/j.bmc.2025.118265_b0040","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1083\/jcb.201103105","article-title":"Release of serine\/threonine-phosphorylated adaptors from signaling microclusters down-regulates T cell activation","volume":"195","author":"Lasserre","year":"2011","journal-title":"J Cell Biol"},{"key":"10.1016\/j.bmc.2025.118265_b0045","doi-asserted-by":"crossref","unstructured":"P.S. Alzabin S, Yee H, Kiefer F, Suzuki A, Burakoff S, Sawasdikosol S., Hematopoietic progenitor kinase 1 is a critical component of prostaglandin E2-mediated suppression of the anti-tumor immune response. Cancer Immunol. Immunother. 2010; 59 (3): 419-429. doi: 10.1007\/s00262-009-0761-0.","DOI":"10.1007\/s00262-009-0761-0"},{"issue":"1","key":"10.1016\/j.bmc.2025.118265_b0050","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.celrep.2018.09.012","article-title":"The Kinase Activity of Hematopoietic Progenitor Kinase 1 Is Essential for the Regulation of T Cell Function","volume":"25","author":"Hernandez","year":"2018","journal-title":"Cell Rep"},{"issue":"3","key":"10.1016\/j.bmc.2025.118265_b0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0212670","article-title":"Critical role of kinase activity of hematopoietic progenitor kinase 1 in anti-tumor immune surveillance","volume":"14","author":"Liu","year":"2019","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.bmc.2025.118265_b0060","doi-asserted-by":"crossref","first-page":"382","DOI":"10.4049\/immunohorizons.1900053","article-title":"HPK1 Influences Regulatory T Cell Functions","volume":"4","author":"Sawasdikosol","year":"2020","journal-title":"Immunohorizons."},{"key":"10.1016\/j.bmc.2025.118265_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116206","article-title":"Discovery of novel, potent, selective and orally bioavailable HPK1 inhibitor for enhancing the efficacy of anti-PD-L1 antibody","volume":"267","author":"Zeng","year":"2024","journal-title":"Eur J Med Chem"},{"issue":"3","key":"10.1016\/j.bmc.2025.118265_b0070","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1021\/acsmedchemlett.0c00660","article-title":"Discovery of Orally Active Isofuranones as Potent, Selective Inhibitors of Hematopoetic Progenitor Kinase 1","volume":"12","author":"Degnan","year":"2021","journal-title":"ACS Med Chem Lett"},{"issue":"11","key":"10.1016\/j.bmc.2025.118265_b0075","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1021\/acsmedchemlett.4c00434","article-title":"Design, Synthesis, and Biological Evaluation of a Series of Spiro Analogues as Novel HPK1 Inhibitors","volume":"15","author":"Peng","year":"2024","journal-title":"ACS Med Chem Lett"},{"issue":"4","key":"10.1016\/j.bmc.2025.118265_b0080","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1021\/acsmedchemlett.1c00096","article-title":"Discovery of Diaminopyrimidine Carboxamide HPK1 Inhibitors as Preclinical Immunotherapy Tool Compounds","volume":"12","author":"Vara","year":"2021","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmc.2025.118265_b0085","doi-asserted-by":"crossref","DOI":"10.1021\/acschembio.1c00819","article-title":"The HPK1 Inhibitor A-745 Verifies the Potential of Modulating T Cell Kinase Signaling for Immunotherapy","author":"Malchow","year":"2022","journal-title":"ACS Chem Biol"},{"issue":"9","key":"10.1016\/j.bmc.2025.118265_b0090","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1021\/acsmedchemlett.4c00319","article-title":"Discovery of GNE-6893, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of HPK1","volume":"15","author":"Tellis","year":"2024","journal-title":"ACS Med Chem Lett"},{"issue":"19","key":"10.1016\/j.bmc.2025.118265_b0095","doi-asserted-by":"crossref","first-page":"17429","DOI":"10.1021\/acs.jmedchem.4c01325","article-title":"Discovery of BAY-405: An Azaindole-Based MAP4K1 Inhibitor for the Enhancement of T-Cell Immunity against Cancer","volume":"67","author":"Mowat","year":"2024","journal-title":"J Med Chem"},{"issue":"4","key":"10.1016\/j.bmc.2025.118265_b0100","doi-asserted-by":"crossref","first-page":"4582","DOI":"10.1021\/acs.jmedchem.4c02631","article-title":"Discovery and Optimization of Pyrazine Carboxamide AZ3246, a Selective HPK1 Inhibitor","volume":"68","author":"Shields","year":"2025","journal-title":"J Med Chem"},{"issue":"4","key":"10.1016\/j.bmc.2025.118265_b0105","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1080\/14728222.2024.2344697","article-title":"Current strategies for targeting HPK1 in cancer and the barriers to preclinical progress","volume":"28","author":"Chen","year":"2024","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.bmc.2025.118265_b0110","unstructured":"BGB-15025 Alone and in Combination with Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants with Advanced Solid Tumors. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04649385 (accessed Jan 17, 2025)."},{"key":"10.1016\/j.bmc.2025.118265_b0115","unstructured":"PF-07265028 as Single Agent and in Combination with Sasanlimab in Advanced or Metastatic Solid Tumors. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05233436 (accessed Jan 17, 2025)."},{"key":"10.1016\/j.bmc.2025.118265_b0120","unstructured":"A Study of NDI 1150\u2013101 in Patients with Solid Tumors. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05128487 (accessed Jan 17, 2025)."},{"key":"10.1016\/j.bmc.2025.118265_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115355","article-title":"Discovery of 7H-Pyrrolo[2,3-d]pyrimidine Derivatives as potent hematopoietic progenitor kinase 1 (HPK1) inhibitors","volume":"254","author":"Wu","year":"2023","journal-title":"Eur J Med Chem"},{"issue":"7","key":"10.1016\/j.bmc.2025.118265_b0130","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1021\/jm1012374","article-title":"Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery","volume":"54","author":"Marsault","year":"2011","journal-title":"J Med Chem"},{"issue":"11","key":"10.1016\/j.bmc.2025.118265_b0135","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.4155\/fmc.12.93","article-title":"Macrocycles in new drug discovery","volume":"4","author":"Mallinson","year":"2012","journal-title":"Future Med Chem"},{"key":"10.1016\/j.bmc.2025.118265_b0140","doi-asserted-by":"crossref","unstructured":"H.S. Driggers EM, Lee J, Terrett NK, The exploration of macrocycles for drug discovery--an underexploited structural class. Nat. Rev. Drug Discov. 2008; 7 (7): 608-624. doi: 10.1038\/nrd2590.","DOI":"10.1038\/nrd2590"},{"key":"10.1016\/j.bmc.2025.118265_b0145","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2021.659845","article-title":"Macrocycle-Antibiotic Hybrids: A Path to Clinical Candidates","volume":"9","author":"Surur","year":"2021","journal-title":"Front Chem"},{"issue":"6","key":"10.1016\/j.bmc.2025.118265_b0150","doi-asserted-by":"crossref","first-page":"6230","DOI":"10.3390\/molecules18066230","article-title":"Macrocyclic drugs and synthetic methodologies toward macrocycles","volume":"18","author":"Yu","year":"2013","journal-title":"Molecules"},{"key":"10.1016\/j.bmc.2025.118265_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116234","article-title":"Macrocycles and macrocyclization in anticancer drug discovery: Important pieces of the puzzle","volume":"268","author":"Zhang","year":"2024","journal-title":"Eur J Med Chem"},{"issue":"15","key":"10.1016\/j.bmc.2025.118265_b0160","doi-asserted-by":"crossref","first-page":"6843","DOI":"10.1021\/acs.jmedchem.8b01985","article-title":"Structure-Based Macrocycle Design in Small-Molecule Drug Discovery and Simple Metrics To Identify Opportunities for Macrocyclization of Small-Molecule Ligands","volume":"62","author":"Cummings","year":"2019","journal-title":"J Med Chem"},{"issue":"3","key":"10.1016\/j.bmc.2025.118265_b0165","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.tips.2021.11.008","article-title":"Targeting intracellular protein-protein interactions with macrocyclic peptides","volume":"43","author":"Buyanova","year":"2022","journal-title":"Trends Pharmacol Sci"},{"issue":"10","key":"10.1016\/j.bmc.2025.118265_b0170","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/S1359-6446(04)03069-7","article-title":"Ligand efficiency: a useful metric for lead selection","volume":"9","author":"Hopkins","year":"2004","journal-title":"Drug Discov. Today."},{"key":"10.1016\/j.bmc.2025.118265_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2025.118079","article-title":"Design, Synthesis, and biological evaluation of 7H-Pyrrolo[2,3-d]pyrimidines as potent HPK1 kinase inhibitors","volume":"119","author":"Wu","year":"2025","journal-title":"Bioorg Med Chem"},{"issue":"41","key":"10.1016\/j.bmc.2025.118265_b0180","doi-asserted-by":"crossref","first-page":"34091","DOI":"10.1074\/jbc.M112.371062","article-title":"Attenuation of T cell receptor signaling by serine phosphorylation-mediated lysine 30 ubiquitination of SLP-76 protein","volume":"287","author":"Wang","year":"2012","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.bmc.2025.118265_b0185","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1177\/2472555220952071","article-title":"Development of High-Throughput Assays for Evaluation of Hematopoietic Progenitor Kinase 1 Inhibitors","volume":"26","author":"Lacey","year":"2021","journal-title":"SLAS Discovery"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089625002068?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089625002068?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T02:39:41Z","timestamp":1775097581000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089625002068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":37,"alternative-id":["S0968089625002068"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2025.118265","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis and structure-activity relationship studies of novel macrocyclic 2,4-diaminopyrimidines as HPK1 inhibitors","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2025.118265","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118265"}}